Nervotec
Provides software for contactless measurement of physiological biomarkers through ordinary cameras.
Website: https://nervotec.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Company | Nervotec |
| Tagline | Provides software for contactless measurement of physiological biomarkers through ordinary cameras. [IMDA, June 2024] |
| Headquarters | Singapore, Singapore [Crunchbase, retrieved 2024] |
| Founded | 2020 [CB Insights, November 2022] |
| Stage | Seed [CB Insights, November 2022] |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth profile | Venture Scale |
| Founding team | Solo Founder |
| Founder | Jonathan Lau [British Chamber of Commerce Singapore, retrieved 2026] |
| Funding label | Seed [CB Insights, November 2022] |
| Total disclosed funding | $180,000 [CB Insights, November 2022] |
Links
From the public record
- Website: https://nervotec.com/
- LinkedIn: https://sg.linkedin.com/company/nervotec
The Short Version
PUBLIC Nervotec builds software that uses ordinary cameras to estimate physiological biomarkers without a wearable, a proposition that is worth tracking because it sits at the intersection of remote health monitoring, insurer distribution, and lower-friction screening workflows [IMDA, June 2024] [CB Insights, retrieved 2024]. Founded in Singapore in 2020, the company traces its origin to founder and CEO Jonathan Lau’s experience as a former fighter pilot, where the initial problem was monitoring human readiness and vital signs in a practical way, according to IMDA and Prestige coverage [IMDA, June 2024] [Prestige, 2022].
The product case is straightforward: Nervotec says its platform uses video-based photoplethysmography to read subtle changes in reflected light from the skin and estimate measures such as heart rate and oxygen saturation through a phone or computer camera, which removes the need for dedicated hardware in some use cases [IMDA, June 2024]. Public sources also point to commercial relationships that give the story more weight than a pure concept-stage pitch, including reported work with Kajima during the pandemic and a Prudential integration through the Pulse by Prudential app [IMDA, June 2024] [CB Insights, retrieved 2024].
The team picture is thinner than the product narrative, but the core public record consistently identifies Lau as founder and director, while other team references remain only partially substantiated in public databases [British Chamber of Commerce Singapore] [F6S]. On capitalization, the company appears seed stage with disclosed funding reported at either $180,000 by CB Insights or $144.4k by F6S, which is a small base even by early healthtech standards and suggests investors should treat capital efficiency and partnership-led distribution as central to the near-term story [CB Insights, November 2022] [F6S].
The business model is described as SaaS and, in the company’s own positioning, "Healthcare as a Service," aimed at remote and contactless measurement across mobile platforms [F6S] [CB Insights, retrieved 2024]. Over the next 12 to 18 months, the key public markers to watch are whether medical-use certification moves from "on track" to completed, whether camera-based measurement expands beyond wellness and screening into regulated workflows, and whether additional named customers or repeatable deployment patterns emerge outside the early partnership set [IMDA, June 2024] [Medgate Today, July 2024].
Unconfirmed -- This section relies materially on company-linked profiles and a small number of public secondary sources; funding is partially corroborated, but several product and commercialization claims remain company-originated or single-source.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed, total disclosed approximately $180,000 [CB Insights, November 2022] |
The Company in Brief
PUBLIC
Nervotec is a Singapore-based healthtech company founded in 2020, focused on software that measures physiological biomarkers through ordinary cameras rather than dedicated hardware [Crunchbase, retrieved 2024] [Nervotec, retrieved 2024]. Public company materials describe the business as a contactless, software-led monitoring platform, while Startup taxonomy sources classify it at seed stage with a SaaS model [Crunchbase, retrieved 2024] [Nervotec, retrieved 2024].
The public record on incorporation is thinner than the product narrative, but there is at least one clear legal-entity reference: Jonathan Lau is identified as founder and director of Nervotec Pte Ltd by the British Chamber of Commerce Singapore [British Chamber of Commerce Singapore, retrieved 2026]. Headquarters are listed in Singapore, which aligns across the company profile and database sources [Crunchbase, retrieved 2024] [Nervotec, retrieved 2024].
The milestone timeline is short and, for now, mostly financing-led. Crunchbase and the company website support a 2020 founding date, and CB Insights records a seed round of $180,000 on November 10, 2022 [Crunchbase, retrieved 2024] [Nervotec, retrieved 2024] [CB Insights, November 2022]. By 2024, the company was publicly presenting its platform as contactless health measurement software and describing commercial activity through its website, which is the clearest public marker that the business had moved beyond concept stage, even if operating metrics remain limited in public filings [Nervotec, retrieved 2024].
Single-source, plausible -- Confirmed in part by Crunchbase and the company website; the legal-entity reference relies on a separate directory source, and the milestone record remains limited in public filings.
What They Have Built
MIXED Nervotec is selling a simple user experience around a technically specific sensing method: ordinary phone or computer cameras are used to estimate physiological signals without a dedicated wearable [IMDA, June 2024]. Public descriptions point to video-based photoplethysmography, or PPG, where software reads subtle changes in reflected light from the skin to infer vital signs such as heart rate, respiration rate, heart-rate variability, and oxygen saturation [IMDA, June 2024] [CB Insights]. The company has framed this as a software-only, contactless monitoring product across mobile platforms, with the stated benefit being lower friction for remote screening or wellness checks than a hardware-dependent workflow [F6S] [IMDA, June 2024].
The evidence on feature depth is narrower than the positioning suggests. Verified public descriptions support camera-based measurement of heart rate and oxygen saturation through Nervotec's Awareness mobile application, and broader claims around stress and heart-health insights appear in company-profile sources and press coverage rather than a detailed product document or clinical methods page [CB Insights] [Prestige, 2022]. IMDA reported in June 2024 that the platform was "on track to being certified for medical use" for applications such as telehealth consultations, which supports regulatory intent but does not establish completed certification as of that date [IMDA, June 2024].
Publicly named deployments give some sense of product surface, even if they do not fully resolve technical performance. IMDA said Nervotec worked with Kajima on health monitoring during the Covid-19 period, while CB Insights said Prudential integrated the technology into Pulse by Prudential so users could measure vital signs by scanning their face with a mobile phone [IMDA, June 2024] [CB Insights, November 2022]. Separate trade coverage in 2024 also described a partnership with Fischer Medical Ventures to support screening for blood pressure, haemoglobin, and HbA1C through camera-enabled devices, but those claims should be treated carefully until backed by primary technical validation or regulatory documentation [Medgate Today, July 2024] [Pharmabiz].
Unconfirmed -- Core product descriptions are supported by public sources, but many capability claims remain company-profile or press-level statements with limited independent technical corroboration.
Market Size and Demand
PUBLIC This market matters now because the cost of measuring basic physiological signals is falling toward software, while employers, insurers, and care providers are still looking for lower-friction ways to screen people outside clinical settings [IMDA, June 2024].
The constraint here is not product narrative, it is market evidence. No cited third-party market-sizing report in the source set directly quantifies the addressable market for camera-based physiological measurement, remote photoplethysmography, or contactless vital-sign monitoring as a standalone category, so any TAM or SAM discussion has to stay qualitative rather than pretend precision. What the public record does show is that Nervotec is aiming at a broad set of existing spending pools, including insurance, healthcare, construction, government, airlines, hospitals, professional sports, and workplace safety, with a software product that uses ordinary cameras instead of dedicated wearables [F6S, retrieved 2024] [CB Insights, retrieved 2024] [IMDA, June 2024].
That framing suggests Nervotec is not creating a net-new budget line so much as competing for portions of adjacent budgets already allocated to telehealth workflows, workforce health screening, wellness apps, occupational safety programs, and device-based monitoring. The practical implication is mixed. A broad budget surface can expand the top of funnel, but it also means adoption depends on whether camera-based measurement is accurate enough, approved enough, and easy enough to displace incumbent workflows in each buyer segment [IMDA, June 2024].
| Segment or adjacent market | Public evidence from sources | Relevance to Nervotec |
|---|---|---|
| Telehealth consultations | IMDA said Nervotec was "on track to being certified for medical use" in applications such as telehealth consultations as of June 2024 [IMDA, June 2024] | Suggests a clinical or near-clinical software pathway if certification is completed |
| Insurance and consumer wellness apps | CB Insights said Prudential integrated Nervotec capabilities into Pulse by Prudential for face-scan vital sign measurement [CB Insights, retrieved 2024] | Indicates a distribution path through insurers and consumer-facing health apps |
| Construction and workplace safety | IMDA reported work with Kajima on health monitoring during the COVID-19 period [IMDA, June 2024] | Points to occupational health and on-site screening as a non-hospital use case |
| Wearable substitution | IMDA described the product as monitoring without a dedicated wearable, using phone or computer cameras [IMDA, June 2024] | Frames the product as a substitute for some light-monitoring use cases rather than a full device replacement |
The table underscores where the commercial logic likely sits. The nearer-term opportunity appears to be in adjacent markets where fast screening and low hardware overhead matter more than continuous medical-grade monitoring, particularly insurer distribution and workplace workflows [CB Insights, retrieved 2024] [IMDA, June 2024].
Demand drivers in the cited material are fairly consistent even if they are mostly company-profile level. The first is convenience: users can obtain a reading by looking at a phone or computer camera, which removes device provisioning and wearability friction from the workflow [IMDA, June 2024]. The second is software distribution. Nervotec positions itself as a software-only, cross-mobile-platform offering, which in theory suits insurers, employers, and telehealth operators that want to layer screening into an existing digital experience rather than mail out hardware [F6S, retrieved 2024].
There is also a post-pandemic demand pattern visible in the named deployments. Kajima's use during the COVID-19 period points to screening and workforce monitoring needs, while the Prudential integration points to population-scale engagement through an app channel rather than a clinic-first motion [IMDA, June 2024] [CB Insights, retrieved 2024]. Those are sensible entry points for this type of technology because they value reach and repeatability, though the cited sources do not establish conversion, retention, or paid expansion.
The nearest substitute markets are wearables, conventional vital-sign devices, and manual telehealth intake. Nervotec's wedge is strongest where a buyer wants a quick estimate of heart rate, oxygen saturation, respiration, or related stress indicators without asking the user to own a separate sensor [CB Insights, retrieved 2024] [TODAY, retrieved 2026] [Prestige, 2022]. It is weaker, at least on public evidence, in settings that require continuous monitoring, deeply regulated diagnostics, or hardware-linked reimbursement, because the sources stop short of showing completed medical certification or broad clinical validation [IMDA, June 2024].
Regulation is the central market-shaping force in the current record. IMDA reported in June 2024 that the platform was on track for medical-use certification, but that wording is prospective and does not confirm approval was obtained [IMDA, June 2024]. That matters because the difference between a wellness tool, a workforce-screening product, and a clinically trusted monitoring layer is not only commercial, it is regulatory. The same software can address very different budget pools depending on what claims it is allowed to make and what level of validation a buyer requires.
Macro conditions cut both ways. On one side, health systems, insurers, and employers continue to look for lower-cost digital monitoring methods that can operate through devices people already have, which is the clearest structural tailwind for camera-based measurement [IMDA, June 2024] [F6S, retrieved 2024]. On the other, budget owners have become more selective about software adoption, especially in health workflows where proof thresholds are higher than in general SaaS. For Nervotec, the market case is credible at the adjacency level, but the size of the attainable market still depends on evidence of regulatory clearance, validated accuracy, and repeat deployment beyond named pilots and partnerships [IMDA, June 2024] [CB Insights, retrieved 2024].
Unconfirmed -- This section relies primarily on company-profile and ecosystem sources, with no independent third-party market-sizing report in the source set and several material market claims supported only by company-adjacent descriptions [IMDA, June 2024] [F6S, retrieved 2024] [CB Insights, retrieved 2024].
Who Else Is Fighting for This
MIXED Nervotec is positioned less against a single named peer than against a stack of alternatives, wearable sensors, telehealth peripherals, and broader health platforms that already control user distribution, which makes the competitive question one of workflow fit rather than pure model performance [IMDA, June 2024] [CB Insights, retrieved 2024] [F6S, retrieved 2024].
The public record supports three competitive layers. First are direct substitutes for the core user job of measuring vital signs remotely, which today are still dominated in practice by wearables and clinical devices rather than camera-only software, given their established role in health monitoring and telehealth workflows [IMDA, June 2024]. Second are distribution-heavy platforms that can embed biometric features inside a broader consumer or enterprise health product, where Prudential's Pulse app is relevant because it shows the buyer may value access to users and engagement loops as much as the sensing method itself [CB Insights, retrieved 2024]. Third are sector-specific service providers in construction, insurance, hospitals, and workplace safety, where Nervotec appears to sell into an existing operational workflow instead of creating a new category from scratch [F6S, retrieved 2024] [IMDA, June 2024].
That framing leaves Nervotec with a visible but still narrow edge. The company has a product story that avoids dedicated wearables, and that matters in settings where compliance, hardware logistics, or per-user device cost can block deployment [IMDA, June 2024]. It also has at least some evidence of channel access through Prudential and Kajima, plus programmatic support from Huawei Spark Incubator Programme and Business Innovations Generator, which gives the company more credibility than a concept-stage entrant [CB Insights, November 2022] [CB Insights, retrieved 2024] [IMDA, June 2024]. The limitation is durability: distribution borrowed through partners is usually perishable unless it converts into proprietary datasets, regulated approvals, or long-term embedded contracts, and the public evidence does not yet establish any of those at scale [IMDA, June 2024] [CB Insights, retrieved 2024].
The exposure is easier to see than the moat. Prudential is both a useful reference point and a reminder that large platforms can absorb the end-user relationship while keeping vendors behind the glass, especially when the feature is one module inside a broader health app [CB Insights, retrieved 2024]. Kajima shows a second exposure: in workplace and construction use cases, the customer may ultimately prefer a bundled safety or occupational-health offering rather than a standalone biomarker layer, which can compress pricing power for a software-only vendor unless the measurements are clinically trusted or operationally indispensable [IMDA, June 2024]. The company's stated path toward medical-use certification could improve that position, but as of June 2024 the reporting only said it was "on track" for certification, not that approval had been completed [IMDA, June 2024].
The most plausible 18-month scenario is that camera-based measurement remains a feature market before it becomes a company-defining market. If certification progress and partner rollouts convert into repeat deployments, Nervotec is the most plausible winner in low-friction screening workflows where avoiding wearables is the central buying criterion, particularly in insurer-led or employer-led channels already accustomed to remote engagement [IMDA, June 2024] [CB Insights, retrieved 2024]. If those milestones slip, the more likely loser is the standalone camera-only category itself, because buyers can continue to rely on incumbent devices for accuracy-sensitive use cases and on established apps such as Prudential's Pulse for distribution-sensitive ones [CB Insights, retrieved 2024] [IMDA, June 2024].
Opportunity
PUBLIC
The prize here is not a better wellness app, it is the chance to become a low-friction measurement layer for remote health screening wherever a standard camera already sits, from insurer apps to telehealth workflows to workforce check-ins [IMDA, June 2024] [CB Insights, retrieved 2024] [F6S, retrieved 2024].
The headline opportunity is straightforward. If Nervotec can turn camera-based biomarker estimation into a trusted software component, it could become one of the few healthtech vendors that expands access without asking users to buy hardware first [IMDA, June 2024]. That matters because the public evidence already shows two ingredients that are usually hard to secure at seed stage: a product story tied to ordinary smartphones and computers, and early distribution through established channels such as Prudential's Pulse app and work with Kajima during the pandemic [IMDA, June 2024] [CB Insights, retrieved 2024]. The opportunity remains conditional on validation and certification, but the path is visible enough to discuss as an execution question rather than a purely conceptual one, especially with IMDA reporting in June 2024 that the platform was on track for medical-use certification in telehealth contexts [IMDA, June 2024].
A useful way to frame the upside is through a small number of concrete growth paths rather than a single all-or-nothing outcome.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Embedded insurer distribution | Nervotec becomes the biometric measurement layer inside insurance and health engagement apps across Asia | The Prudential Pulse relationship expands from a named app integration into repeat deployments with additional insurers or employer-linked health products [CB Insights, retrieved 2024] | The product already fits mobile distribution, and CB Insights identifies a live Prudential use case where users scan their face to measure vital signs [CB Insights, retrieved 2024] |
| Telehealth compliance wedge | Nervotec wins adoption as a pre-consultation or triage module for remote care providers | Medical-use certification or equivalent regulatory acceptance for defined use cases [IMDA, June 2024] | IMDA reported the company was pursuing certification for telehealth applications, which is the kind of gating event that can convert a novel feature into purchasable clinical software [IMDA, June 2024] |
| Camera-based screening platform | Nervotec broadens from core vitals into a wider software stack for remote screening, including blood pressure and metabolic markers through partners | The July 2024 partnership with Fischer Medical Ventures translates into commercial products and reference deployments [Medgate Today, July 2024] [Pharmabiz] | Public reporting already ties the company to expanded screening ambitions beyond heart rate and oxygen saturation, suggesting a path from a single-use tool to a broader measurement platform [Pharmabiz] |
The compounding mechanism, if it appears, would come from distribution and trust more than from consumer virality. Each successful deployment inside an insurer, enterprise health program, or telehealth workflow can lower customer acquisition costs for the next one because the company is selling software that runs on existing camera-equipped devices, not shipping new hardware into the field [IMDA, June 2024] [F6S, retrieved 2024]. That software-only posture also creates room for product expansion: start with heart rate and oxygen saturation, then move into adjacent biomarkers or workflow features once the buyer has already integrated the core measurement layer [CB Insights, retrieved 2024]. The early signs of this are modest but real in the public record, namely a named insurer integration, a construction-sector use case, and a later partnership aimed at adding blood pressure, haemoglobin, and HbA1C screening through camera-enabled devices [CB Insights, retrieved 2024] [IMDA, June 2024] [Pharmabiz].
The size of the win is still best expressed as a scenario, not a forecast, because the public record does not provide the revenue base needed for a tighter valuation frame. In the upside case, Nervotec could become a strategic infrastructure asset in digital health, valuable less for brand and more for being embedded inside large existing channels such as insurers, providers, and workforce platforms [CB Insights, retrieved 2024] [IMDA, June 2024]. If the telehealth-certification path lands and the insurer distribution model repeats across several markets, the outcome could resemble a scarce acquisition target for a health insurer, digital care platform, or medical-device company that wants camera-based remote measurement without building it in-house (scenario, not a forecast) [IMDA, June 2024] [Medgate Today, July 2024]. With only about $180,000 in disclosed funding on CB Insights, the asymmetry is what stands out: the company is still financed like a small experiment, but the addressable workflow, if validated, sits inside much larger healthcare and insurance budgets [CB Insights, November 2022].
Single-source, plausible -- This section relies on one to two public sources for most claims, with material upside assumptions anchored mainly in IMDA, CB Insights, and partnership coverage rather than independent operating disclosures.
Sources
From the public record
[IMDA, June 2024] Healthtech Evolution: A Tale of Two Startups | https://www.imda.gov.sg/resources/blog/blog-articles/2024/06/healthtech-evolution-a-tale-of-two-startups
[Crunchbase, retrieved 2024] Nervotec - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/nervotec
[CB Insights, November 2022] Nervotec Stock Price, Funding, Valuation, Revenue & Financial Statements | https://www.cbinsights.com/company/nervotec/financials
[CB Insights, retrieved 2024] Nervotec Stock Price, Funding, Valuation, Revenue & Financial Statements | https://www.cbinsights.com/company/nervotec/financials
[Prestige, 2022] Former Fighter Pilot Jonathan Lau's New Mission in Health Tech | https://www.prestigeonline.com/sg/people-events/people/former-fighter-pilot-jonathan-lau-new-mission-health-tech/
[British Chamber of Commerce Singapore, retrieved 2026] Entrepreneur of the Year Award | https://britcham.org.sg/entrepreneur-award/
[F6S, retrieved 2024] Nervotec | https://www.f6s.com/companies/digital-health/singapore/co
[Medgate Today, July 2024] Fischer Medical Ventures and Nervotec Announce Global Partnership to rework Chronic Health Screening with Ordinary Camera-Enabled Devices | https://medgatetoday.com/fischer-medical-ventures-and-nervotec-announce-global-partnership-to-revolutionise-chronic-health-screening-with-ordinary-camera-enabled-devices/
[Nervotec, retrieved 2024] Predictive Healthcare Technology Company Singapore | Nervotec | https://nervotec.com/
[TODAY, retrieved 2026] These S'pore start-ups are using AI to transform healthcare, from cutting medical errors to making screenings less invasive | https://www.todayonline.com/features/these-spore-start-ups-are-using-ai-transform-healthcare-cutting-medical-errors-making-screenings-less-invasive-2448541
[Pharmabiz] Fischer Medical Ventures partners with Nervotec to transform chronic health screening with camera-enabled devices | https://www.pharmabiz.com/NewsDetails.aspx?aid=171881&sid=2
Articles about Nervotec
- A Fighter Pilot's Idea Is Measuring Vitals Through a Phone Camera — The Singapore startup is testing its video-based photoplethysmography with insurers and construction firms, targeting a future as certified medical software.